NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) announced completion of a 90-patient Phase 2 study evaluating its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results